All In Biotech

Drug Trial Radar · NCT05075824

A Study Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Crovalimab as Adjunct Treatment in Prevention of Vaso-Occlusive Episodes (VOE) in Sickle Cell Disease (SCD)

A Randomized Double-Blind Phase IIA Study Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Crovalimab as Adjunct Treatment in Prevention of Vaso-Occlusive Episodes (VOE) in Sickle Cell Disease (SCD)

Last checked: Nov 20, 2026Latest source record: Apr 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

95

Actual

Start

Mar 9, 2022

Primary completion

Jun 11, 2025

Study completion Apr 9, 2026

Sponsor

Lead sponsor
Hoffmann-La RocheRoche (Genentech) (RHHBY)
Sponsor type
Industry
First posted
Oct 13, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years, up to 55 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is designed to evaluate the efficacy, safety and pharmacokinetics of crovalimab compared with placebo as adjunct therapy in the prevention of VOEs in participants with SCD.

Conditions

  • Sickle Cell Disease

Interventions

  • CrovalimabDrug

    Crovalimab will be administered at a dose of 1000 mg IV (for participants with body weight between 40 kg and 100 kg) or 1500 mg IV (for participants with body weight \>= 100 kg) on Week 1 Day 1. On Week 1 Day 2 and on Weeks 2, 3 and 4, crovalimab will be administered at a dose of 340 mg SC. For Week 5 and Q4W thereafter, crovalimab will be administered at a dose of 680 mg SC (for participants with body weight between 40 kg and 100 kg) or 1020 mg SC (for participants with body weight \>= 100 kg). Dosing schedule will be as per Arm Description.

  • PlaceboDrug

    Matching Placebo will be administered with the same dosing schedule and equivalent IV and SC volume as weight-based Crovalimab.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Annualized rate of medical facility VOEs (AVR)Time frame: Baseline up to Week 49

Locations

27 sites in 11 countries. Site status is shown where the registry gives one.

  • Children's Hospital of Michigan

    Detroit, Michigan

  • Mississippi Center for Advanced Medicine

    Madison, Mississippi

  • Icahn School of Medicine at Mount Sinai

    New York, New York

  • East Carolina University

    Greenville, North Carolina

  • HEMORIO

    Rio de Janeiro, Brazil

  • Hospital Samaritano

    São Paulo, Brazil

  • Hospital Sao Rafael - HSR

    Salvador, Estado de Bahia, Brazil

  • Hospital das Clinicas - UFRGS

    Porto Alegre, Rio Grande do Sul, Brazil

  • UNESP - Faculdade de Medicina da Universidade Estadual Paulista - Campus Botucatu

    Botucatu, São Paulo, Brazil

  • Hospital das Clínicas Faculdades Médicas de Ribeirão Preto

    Ribeirão Preto, São Paulo, Brazil

  • Hospital de Base de Sao Jose do Rio Preto

    São José do Rio Preto, São Paulo, Brazil

  • Beneficencia Portuguesa de Sao Paulo

    São Paulo, São Paulo, Brazil

  • CHU Henri Mondor

    Créteil, France

  • Università degli Studi della Campania Luigi Vanvitelli

    Naples, Campania, Italy

  • Azienda Ospedaliera di Verona-Policlinico G.B. Rossi

    Verona, Veneto, Italy

  • International Cancer Institute (ICI)

    Eldoret, Kenya

  • Gertrude's Children Hospital

    Nairobi, Kenya

  • Hopital Nini

    Tripoli, Lebanon

  • Amsterdam UMC Location VUMC

    Amsterdam, Netherlands

  • Charlotte Maxeke Johannesburg Hospital

    Johannesburg, South Africa

  • Hospital General Univ. Gregorio Maranon

    Madrid, Spain

  • Hospital Universitario Miguel Servet

    Zaragoza, Spain

  • Adana Acibadem Hospital; Pediatric Hematology

    Adana, Turkey (Türkiye)

  • Cukurova University Medical Faculty Balcali Hospital

    Adana, Turkey (Türkiye)

  • Mersin Universitesi Tip Fakultesi Hastanesi

    Mersin, Turkey (Türkiye)

  • Central Middlesex Hospital

    London, United Kingdom

  • Hammersmith Hospital

    London, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.